Global R&D Center focuses on the R&D of new-modality chemical drugs, with deployments in molecular glues/PROTACs, oligonucleotides, peptides and antibody-drug conjugates (xDCs). By integrating AI-driven digitalization with advanced technologies such as organoids, the company has established end-to-end full-chain R&D capabilities. Its self-developed Class 1 innovative drug Fu Mai Ning (luvometinib tablets) has been approved as the first and only innovative drug in China that covers both Langerhans-cell histiocytosis (LCH) and neurofibromatosis type 1 (NF1), two rare diseases, while providing treatment coverage across all age groups from children to adults. As of August 2026, the company has 59 pipeline assets and is conducting 18 clinical trials, focusing on major areas of unmet clinical need including oncology, immune inflammation and central nervous system diseases. Through multiple collaboration models including original innovation, out-licensing and joint development, the company strives to become a globally competitive innovative pharmaceutical company benefiting patients worldwide.

YaoPharma is a core member enterprise of Fosun Pharma. Founded in 1939, it is a national key high-tech enterprise integrating API and formulation R&D, manufacturing and commercialization. Focusing on the innovation direction of "New, First and Difficult", YaoPharma has built a research and development system that combines generics and innovative drugs, and formed four innovative platforms: microchannel continuous reaction, impurity separation and synthesis, difficult injectables and sustained/controlled release drug delivery systems. Regarding globalization, its key API products have passed U.S. and European cGMP certifications, with over 75% exported to the U.S. and European markets. In formulations, YaoPharma is the first pharmaceutical manufacturer in China with prescription medicine passing Canadian cGMP certification, and the first pharmaceutical manufacturer in western China with oral solid line passing US cGMP certification. Looking ahead, YaoPharma is committed to becoming an innovation-led international pharmaceutical company.

Avanc Pharma is a wholly-owned subsidiary of Fosun Pharma. It has a long-term commitment to perioperative, cardiovascular, neurological, anti-tumor and pediatric therapeutic areas, and has built a rich R&D pipeline covering innovative drugs, improved new drugs and high-barrier generics, with more than 30 products under development. Adhering to the strategy of "endogenous growth, exogenous expansion and integrated development", Avanc Pharma strives to become a domestic leader with global competitiveness.